antibody B9 was produced from fusion of NS-1 cells with spleen cells from a mouse immunized with 7.12 Fab. In an enzyme-linked immunosorbent assay and immunoprecipitation, B9 reacted with 7.12, polyclonal rabies virus immune dog serum, and purified AChR. The binding of B9 to 7.12 and immune dog serum was inhibited by AChR. B9 also inhibited the binding of 7.12 to rabies virus both in vitro and in vivo. Indirect immunofluorescence revealed that B9 reacted at neuromuscular junctions of mouse tissue. B9 also reacted in indirect immunofluorescence with distinct neurons in mouse and monkey brain tissue as well as with PC12 cells.
B9 staining of neuronal elements in brain tissue of rabies virus-infected mice was greatly reduced. Rabies virus inhibited the binding of B9 to PC12 cells. Mice immunized with B9 developed low-titer rabies virus-neutralizing antibody. These mice were protected from lethal intramuscular rabies virus challenge. In contrast, anti-idiotypic antibody raised against nucleocapsid antibody 7.25 did not react with AChR.
Areas of controversy exist regarding the pathogenesis of rabies virus in the early stages of infection (53) . There is a general consensus that the virus enters peripheral nerves at nerve endings in muscle tissue (8, 17, 43, 64) . However, there is little agreement beyond that essential point. Whether virus entry involves sensory or motor nerves is subject to differing opinions (5, 8) . Whether the uptake of rabies virus is mediated by the acetylcholine receptor (AChR) is also subject to dissenting views (32, 46, 54) .
Rabies virus has been found localized at neuromuscular junctions (NMJ) by immunofluorescence (IFA) and electron microscopy of both intact muscle and isolated NMJ (5) . Virus binding to chick myotubes was inhibited by cholinergic antagonists, which bind to the AChR (32, 60) . However, the fact that rabies virus binds to other types of cultured cells that have no AChR was recognized initially (32) and led some investigators to question whether the AChR is an important receptor for rabies virus (60) .
In addition, rabies virus spreads through the central nervous system transsynaptically (19, 50) . It has been suggested that spread through nerves involves endings other than a nicotinic AChR (29) . While a nicotinic AChR has been isolated from rat brain (65) , the nature of some nerve endings through which rabies virus spreads is unknown (29) . Thus, there are questions as to whether there are multiple receptors for rabies virus: one or more for cells in culture and two or more in the nervous system, whether central or peripheral (31) .
Biochemical methods have been used in an attempt to resolve the question of the relationship between the AChR and rabies virus. The amino acid sequence of the rabies virus glycoprotein was shown to possess homology with those of * Corresponding author. snake venom toxins that bind to the AChR (35) . Furthermore, synthetic peptides based on these regions of homology bound to the AChR (34) and behaved as AChR antagonists (47) .
While these biochemical results provided additional support for the hypothesis that rabies virus binding might involve the AChR, they were not biologically conclusive. Sequence homologies can be misleading. For example, there is a low-level amino acid sequence homology between rabies virus glycoprotein and the c-myc protein. However , rabies virus has no transforming function and localizes to the cell surface (6) . In addition, these biochemical experiments did not address the complexity of the concept of multiple virus receptors raised by other studies (29, 32, 46, 54) . Thus, additional efforts were required to establish whether the sequence homologies between toxins and the rabies virus glycoprotein are biologically significant.
One approach that addresses biologic significance is based on the idiotype-anti-idiotype network (22) . The rationale for using this approach is based on the theory that antigen is recognized and bound by an antibody (Abl) because the antigen binding site (paratope) on Abl is, to a greater or lesser degree, complementary to an epitope on the antigen. If anti-idiotypic antibodies (Ab2) are made against Abl, a proportion will possess paratopes that are complementary to the Abl paratope. These Ab2 paratopes may mimic the original antigen and display properties of the antigen.
Work previously done in our laboratory (5) suggested that an anti-idiotypic response might be used to define a rabies virus receptor at NMJ, as has been done for receptors of other viruses (2, 28, 38, 44) . We found that polyclonal antibodies against rabies virus-neutralizing antibodies bound to AChR (5) . In his review, Spriggs emphasized the importance of repeating these polyclonal antibody anti-idiotypic experiments with hybridoma technology (53) . Subsequently, others referred to the concept, suggesting that the underlying hypothesis was amenable to experimental verification (35) . The purpose of the work described in this report was to test the hypothesis that the AChR is a rabies virus receptor by use of the anti-idiotypic network.
In a review article, UytdeHaag et al. (62) briefly mentioned an experiment in which two different rabbit antiidiotypic antibody preparations against a rat monoclonal anti-AChR antibody reacted with rabies virus. No additional details were given. In the present study, we used a rat monoclonal anti-AChR antibody described by Lindstrom (36) in an effort to make anti-idiotypic antibody reactive with rabies virus. At the same time, we sought to isolate murine rabies virus anti-idiotypic monoclonal antibody reactive with the AChR. Thus, part of the project involved making and testing antibodies to rabies virus proteins. Our (51) . Congo-Crimean hemorrhagic fever (CCHF) virus strain 10200 (59), a nairovirus, was used as a control to monitor specificity. Affinity-purified virus was prepared by use of polyclonal antibody coupled to cyanogen bromideactivated Sepharose 4B as previously described (5) . Neutralization tests in vitro with fluorescent-focus units and CER cells were done as described elsewhere (59 (59, 64) . In comparative IFA tests, each antibody was used at a dilution fourfold lower than the homologous endpoint.
Included in this study were pre-and post-convalescentphase sera from an earlier study in which two dogs, dogs 3 and 4, had been inoculated i.m. with Lagos bat virus, which is related to rabies virus (58) . Serum from dog 3 on day 42 contained in vivo rabies virus-neutralizing antibody. Serum from dog 4 did not contain significant rabies virus-neutralizing antibody (log neutralizing antibody titer, <1.7, or failure to neutralize 50 LD50s of rabies virus). These antisera had been stored at -20°C for 18 years, so tests were done to confirm the presence of rabies virus antibody in the day-42 serum from dog 3 and the absence of significant antibody in the serum from dog 4.
Affinity purification of Torpedo californica AChR. Affinity purification was carried out by the original protocol of Froehner and Rafto (13) as modified by Mosckovitz and Gershoni (42) . Frozen T. califomica (100 g; Pacific Biomarine, Venice, Calif.) was cut in very thin slices, to which was added 100 ml of buffer A [10 mM Tris-HCl (pH 7.4), 100 mM NaCl, 1 mM EDTA, 1 mM ethylene glycol-bis(,B-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), 0.5 mM NaN3, 0.1 mM phenylmethylsulfonyl fluoride (PMSF)]. The mixture was homogenized for 1 min in a Sorvall mixer. The homogenate was filtered through four layers of cheesecloth and subsequently centrifuged at 15,000 rpm for 45 min in a Sorvall SS-34 rotor. The supernatant fluid was discarded, and the pellet was extracted with buffer B (buffer A plus 1%
[wtlvol] Triton X-100; 60 ml of buffer per 100 g of tissue) for 2 h at 4°C. The supernatant fluid was collected and incubated overnight at 4°C with 5 to 6 g of Naja naja siemensis alpha-toxin in an affinity column (Sigma, St. Louis, Mo.). The column was washed sequentially with 150 ml each of buffer B, buffer B with 1 M NaCl, and buffer B with 0.1% (wt/vol) Triton X-100. Bound AChR was eluted by rotating the beads for 2 to 3 h at 4°C with 5 ml of buffer A containing 0.1% (wt/vol) Triton X-100 and supplemented with 1 M carbamylcholine chloride. The eluate was dialyzed against buffer A containing 0.1% Triton X-100. After the addition of PMSF (1 mM), the purified receptor was divided into aliquots and stored at -200C.
Enzyme-linked immunosorbent assay (ELISA) conijugates. Preparation of antibodies and antibody fragments for immunization and the ELISA. Antibodies, isolated by elution from protein A, were tested serologically for reactivity by procedures described previously (5) . Mouse Fab fragments from Igs were made by standard methods (15 ELISA for detection of anti-idiotypic antibody. An ELISA was chosen because it previously had been shown in comparative assays to be useful for the detection of anti-idiotypic antibodies to the anti-AChR immune response (45) . Two different ELISA systems were used to screen for antiidiotypic antibody. In the first ELISA system, immunizing (7.12) and control (CCHF virus) Fab antibodies were used to coat polystyrene plates in dilutions containing similar amounts of protein, none of which could be detected by anti-Fc conjugate. Plates were blocked with 3% gelatin, and then supernatant fluids from hybridoma cultures were added. After incubation and three washes with PBS-0.05% Tween 20, goat anti-mouse Ig Fc conjugate (1:3,000) was added. Positive reactions (i.e., ODs higher than the OD of the CCHF virus control antibody + 3 standard errors) were found when substrate was added after five washes.
In the second ELISA system, affinity-purified AChR (approximately 0.3 to 0.5 mg/ml) was diluted 200-or 300-fold and dispensed into microtiter plates for overnight incubation at 4°C. After being coated, plates were washed three times with assay buffer (2% fetal calf serum in PBS); the third wash was used for blocking (1 h, 4°C (39) . Pelleted (100,000 x g for 2 h) radiolabeled (35S) rabies or CCHF virus from CER cell culture supernatant fluids was solubilized in RIPB buffer (10 mM Tris [pH 7.5], 150 mM NaCl, 5 mM EDTA, 1% Na deoxycholate, 1% Triton X-100) containing protease inhibitors (PMSF, 1 mM; aprotinin, 10 ,g/ml; leupeptin, 2 ,ug/ml; benzamidine, 2 ,ug/ml; and Nct-p-tosyl-L-lysine chloromethyl ketone [TLCK], 10 ,ug/ml). Solubilized viral proteins (50 ,ul) were incubated overnight at 4°C with 1 to 2 ,ul of clarified monoclonal or polyclonal ascites or with antibody 7.12 conjugated to Sepharose beads (Sigma). Material immunoprecipitated by antibody alone was sedimented with protein A-Sepharose beads that had been washed three times with RIPA buffer (RIPB buffer with 0.1% sodium dodecyl sulfate). After being extensively washed with RIPB buffer, proteins were released from the beads by incubation in sample buffer for 5 min at 100°C. The proteins were separated on a 10% acrylamide gel (30) , which was processed for autoradiography with Kodak film. Western blotting was done as previously described (5) . Radiolabeled (1251) cx-bungarotoxin for identification of the alpha subunit of the AChR was purchased from New England Nuclear (Boston, Mass.).
Preparation and use of affinity columns. Anti-idiotypic antibody was precipitated from serum-free hybridoma culture fluid by use of polyethylene glycol 6000 (23) . Concentrated antibody was examined by PAGE and conjugated to cyanogen bromide-activated Sepharose 4B as described previously (5). Purified AChR was added to the anti-idiotypic affinity column. Binding proteins were eluted with pH 3.0 buffer (Bio-Rad Laboratories, Richmond, Calif.). After elution, proteins from the affinity column were concentrated by filtration through a low-molecular-mass protein binding membrane with a 30,000-Da cutoff (Millipore, Bedford, Mass.) and characterized by PAGE. Affinity columns for partial purification of virus were prepared and used as described previously (5 (Fig. IB, lane 1) , as seen elsewhere with other rabies virus anti-glycoprotein monoclonal antibodies (3). These results were duplicated after immunoprecipitation without the antibody 7.12 affinity columns by the method of Mason (39) . The starting virus, partially purified from sucrose gradients, is shown in Fig. 1C, lane 1; the product of the immunoprecipitation is shown in Fig. 1C , lane 2, in which, once again, only the viral glycoproteins were immunoprecipitated. Antibody 7.12-producing hybridoma cells were cloned three times by limiting dilution. Secreted antibody consisted of only one light chain, as determined by PAGE, and immunoprecipitated only the viral glycoproteins. Thus, 7.12 was a monoclonal antibody, as determined by conventional standards. Neither supernatant fluids nor ascites from antibody 7.12-producing cells reacted with rabies virus proteins in Western blotting, suggesting that the antibody recognizes a conformationally dependent glycoprotein epitope.
In contrast to the results obtained with 7CC8, a clone derived from 7CE9 (7.25; IgM isotype) produced antibody that did not neutralize rabies virus. Some mice infected with mixtures of virus and antibody 7.25 occasionally had a prolonged survival time, but neutralization could not be demonstrated (data not shown). These negative neutralization test results were associated with immunoprecipitation of a protein with the approximate mobility of the rabies virus nucleocapsid (Fig. 1A, lane 3) immune serum as the coating reagent were > 1:6,400 whereas B9 antibody did not react (titer, < 1:400) with nonneutralizing dog serum. The negative control sera included prebleed sera from dogs 3 and 4 and day-42 serum from dog 4, which did not make significant (log1o neutralizing index, <1.7) rabies virus-neutralizing antibody after infection with Lagos bat virus.
Reactions of anti-idiotypic B9 antibody with the AChR. One concern was that B9 antibody was reacting with a contaminant of the AChR. Seven different isolations of fish AChR were done with toxin affinity columns. All preparations contained the four AChR subunits; in addition, some preparations contained the 43-kDa polypeptide frequently associated with the four subunits of the AChR (12) (Fig. 2A, lane 2). B9 antibody reacted equally in ELISAs with the different AChR preparations, regardless of how much 43-kDa protein was present. The specificity of the AChR reaction was further established when B9 antibody did not react specifically with chicken embryo membranes (0.25 mg/ml diluted 1:300 in coating buffer).
After solubilized AChR was added to and eluted from a B9 antibody affinity column, the eluted proteins had the PAGE profile seen in Fig. 2B Cumulatively, these data showed that B9 antibody did not react with a contaminant of the AChR. As is true of all monoclonal antibodies to the AChR, the subunit specificity could not be determined without competitive inhibition studies with a battery of AChR monoclonal antibodies (36) However, the fluorescence produced by B9 was more narrowly circumscribed than that produced by Mab35. In morphologic localization, the fluorescence produced by B9 antibody was essentially identical to that described in an earlier publication in which AChR antibodies were used (12) .
IFA examination of alternate serial sections of mouse muscle tissue produced outcomes matching those described above for B9 (Fig. 3A) and Mab35 (Fig. 3B) (20, 21) . For example, pyramidal cells in the hippocampus (Fig. 4a) and Purkinje cells in the cerebellum (Fig. 4b) were intensely reactive. In the hippocampus, the IFA was largely limited to discrete areas on the surface of the pyramidal cells; only an occasional cell in the molecular layer was stained, usually with punctate dots. In their morphology, these IFA-positive elements were suggestive of synaptic boutons (Fig. 4c) . This staining pattern was typical of the reactions on neurons in the olfactory area, the thalamus, and the cerebral cortex. A different type of staining was seen in the cerebellum, in which the Purkinje cell bodies were labeled (Fig. 4b) , sometimes with perinuclear fluorescence. There were numerous punctate dots of fluorescence on granule cells in the cerebellum. In other areas of both the brain and the spinal cord, a third type of staining was seen. Neuronal projections, probably representing nonmyelinated fibers, were stained, sometimes in configurations that resembled synaptic contacts (Fig. 4d) . These both randomly bred and inbred mice. Variations among individual mice examined were not obvious. B9 antibody stained monkey brain tissue as follows. In monkeys, B9 stained mostly pyramidal cells, and the staining was similar in the frontal, motor, and somatosensory cortexes. The negative control IFA antigen was mouse liver tissue. B9 antibody did not react with paraformaldehyde-or formalinfixed tissue (data not shown).
In striking contrast to the reaction with normal pyramidal cells in the murine hippocampus, B9 staining of rabies virus-infected hippocampal cells was greatly diminished, even with undiluted antibody. Serial sections from the brains of moribund mice, infected i.m. with strain 1820B, were treated with polyclonal antibody to strain 1820B (Fig. 5a ) or with undiluted B9 ascites (Fig. 5b) . In six moribund mice examined on two separate occasions, a reduction in B9 reactivity was more clearly defined in the hippocampus than in the cerebellum, in which staining appeared fragmented and disorganized compared with that in normal mice. In earlier stages of the disease course, a reduction in pyramidal cell staining by B9 antibody was less obvious. During these experiments, normal mouse brain tissue was treated with B9 antibody to ensure that the IFA system was working properly. The absence of an intense B9 antibody reaction on infected tissue from moribund mice suggested either that the virus infection destroyed the receptor or that there was (Fig. 6B) . B9-AChR specificity was shown in a separate experiment by a lack of effect after pretreatment of B9 with chicken embryo membrane vesicles, whereas pretreatment with AChR, at a similar protein concentration, significantly reduced reactivity (P < 0.001; paired t test; Fig. 6C ). There was no difference in the B9-AChR reaction whether preincubation was done with control (CCHF virus) antibody or chicken embryo membrane vesicles (Fig. 6A and C) .
The binding of antibody 7.12 to rabies virus in the CER cell ELISA was inhibited by pretreatment of the antibody with B9 at 1:3 (P < 0.0001) and 1:10 (P < 0.0002) dilutions (Fig. 6D) antibody and rabies virus. The experiments described above were necessary for defining B9 as an anti-idiotypic antibody. However, the question of competition between rabies virus and B9 antibody for binding sites remained. We have not yet purified the B9 brain receptor, so this question was indirectly approached in two different ways. First, the effect of rabies virus on B9 binding to the AChR was examined. Affinitypurified rabies virus antigen was used in an ELISA to determine whether rabies virus blocked B9 binding to the AChR. AChR (0.03 mg/ml) was dispensed into a 96-well plate in a 0.1-ml volume for overnight coating at 4°C. Dilutions of partially purified B9 antibody (1 mg/ml) were mixed with an equal volume of affinity-purified rabies virus antigen (approximately 5 ,ug/ml) or CCHF virus control antigen before incubation with AChR. In this ELISA, the detecting antibody was an anti-mouse IgM conjugate used on four replicates. At final dilutions of 1:500 and 1:1,000, the B9-control virus mixture reacted with AChR at mean ODs of The previous experiments demonstrated competition between rabies virus and B9 antibody for binding to musclederived AChR. PC12 cells, which express the alpha subunit of the neural AChR (66) , were also used to demonstrate competitive inhibition between B9 antibody and rabies virus. While B9 antibody did not stain CER or neuroblastoma cells in IFA tests, it did react with PC12 cells. The titer of B9 antibody (supernatant fluid) on acetone-fixed cells (clone T), in wells on printed slides, was >1:100 (Fig. 7a) . After preincubation of PC12 cells (5 x 104 per well) with approximately 108 partially purified rabies virus particles, the titer of B9 antibody was <1:5 ( Fig. 7b) . Preincubation of PC12 cells with similar numbers of eastern equine encephalitis or Sindbis (strain EgAr 339) virus particles did not reduce the B9 antibody titer from .1:100 (Fig. 7c) .
Competitive inhibition (in vivo). Myotube cultures, used in our earlier studies (32) , and PC12 cells could not be used for in vitro competitive inhibition experiments because a suitable semisolid or solid nutrient overlay for quantitating the results does not exist, nor were we able to develop one. In addition, the interpretation of in vitro results would have been complicated by the fact that B9 binds to PC12 cells. However, the inhibition of 7.12 neutralization of rabies virus was demonstrated in vivo, but only when a relatively high concentration of B9 antibody was preincubated with 7.12 antibody. 7.12 antibody in ascites was diluted to 1:64 and mixed with an equal volume of partially purified B9 antibody (3 mg/ml), as in the previous experiment. The mixture was preincubated for 60 min at 37°C. Afterwards, it was mixed and similarly incubated with an equal volume of 1820B virus (100 i.m. adult mouse LD50s). Groups of six adult mice were inoculated with 0.03 ml in the hindlimb. Antibody 7.12 mixed with control antibody (IgM isotype; 3 mg/ml) neutralized virus infectivity; six inoculated mice survived. In antibody from hybridoma culture supernatant fluid were preincubated with control CCHF virus antibody (5 mg of total protein per ml) or with B9 antibody (4 mg of total protein per ml) at either a 1:3 or a 1:10 dilution. The pretreated antibody was titrated in the ELISA on formalin-treated rabies virus-infected or mock-infected CER cells. The background with mock-infected cells has been subtracted for each value shown. The binding of 7.12 to rabies virus was significantly inhibited (P < 0.001) after treatment with a 1:3 dilution of B9 antibody. The reduction in binding was lower after pretreatment with a 1:10 dilution of B9 antibody, but the difference was still significant (P < 0.002). Antibody 7.12 does not neutralize rabies virus on cultured cells that are not known to have the AChR, at least insofar as we have searched. Guidelines, reviewed elsewhere (4), have been used to determine whether B9 is an internal image (Ab2,B) of the virus antigen. B9 fullfils the following criteria, which suggest that it is an internal image. B9 reacts with the AChR, a host cell molecule for which there is significant evidence suggesting that it is a rabies virus receptor. B9 reacts not only with 7.12 but also with a heterologous polyclonal rabies virus antibody from a different species. There is reciprocal competitive inhibition, which is important in the evaluation of an anti-idiotypic antibody (1) . The binding of B9 to affinity-purified AChR is inhibited by 7.12 but not by an irrelevant antibody. B9 binding to the AChR is also inhibited by rabies virus and AChR. Conversely, 7.12 binding to rabies virus is inhibited by preincubation with B9 antibody, both in vivo and in vitro. B9 antibody elicited an antibody response (Ab3) to itself in mice. The response was of a low titer; the low titer could have resulted from immunization with too little B9 or an otherwise inappropriate dose of B9 (11) . Alternatively, the paratope of B9 may not have been perfectly complementary to the paratope of 7.12. However, despite the low neutralizing titers, mice treated with at least one immunization protocol were uniformly protected from i.m. challenge.
There are areas of debate regarding internal images (40) . For example, cross-species reactivity between B9 and rabies virus antibodies could occur if a common Vh germ line gene coding for the idiotope were produced (25) . However, our data suggesting a 21 internal image are supported by those of Rustici et al. (48) . These workers raised monoclonal antibodies to the synthetic fragment of rabies virus glycoprotein (positions 190 to 203) and found, by using affinity chromatography, that the antibodies bound neurotoxins. They believed that their data indicated that the paratope of their monoclonal antibodies behaves as an internal image of the nicotinic cholinergic receptor binding site.
Our data unequivocally show that antibody against rabies First, the epitope recognized by Mab35 is not the rabies virus binding site, as measured by the anti-idiotypic network. Our results with anti-idiotypic antibody to Mab35 parallel very closely those of others who found that antiidiotypes frequently bind cytoskeletal proteins (10) . The observation that anti-idiotypic antibody to 7.25 (antibody against the rabies virus nucleocapsid) also binds cytoskeletal proteins suggests some form of mimickry between the viral and cytoskeletal proteins. This explanation would parallel observations of mimickry in other viral systems but would be quite distinct from the anti-idiotypic network explanation (14) . Whether the cellular cytoskeleton plays a role in rabies virus replication is presently unknown (reviewed in reference 7) . Second, our data may provide an additional explanation for the reported lack of correlation between monoclonal virus-neutralizing antibody titers determined in vitro and protection in vivo (49 Since the effect of the reagents developed in this study depends on whether the host cell expresses the AChR, the question of differential receptors can now be explored in vitro in the type of model system advocated by Koprowski (27) . Rabies virus is certainly not unique in apparently using different receptors on different cultured cell types. In reovirus studies, virus binding to idiotype-negative cells was not inhibited by anti-idiotypic antibody, although these cells were susceptible to virus infection (24) .
Finally, the question of multiple receptors in vivo is somewhat better resolved by the results of this study. The AChR epitope recognized by B9 at the peripheral NMJ is also present in the central nervous system. However, there may be multiple receptors in the nervous system. A variety of escape mutants of rabies virus have been isolated on the basis of their acquired resistance to neutralizing monoclonal antibodies directed to the viral glycoprotein. Lafay et al. (31) suggested that the pathogenic strain of rabies virus (CVS) should be able to bind several different kinds of receptors to penetrate neurons, while the nonpathogenic virus strain (AvOl) would be unable to recognize some of them. On the other hand, Dietzschold et al. (9) found that pathogenic viruses spread within the brain more rapidly than nonpathogenic viruses. Tuffereau et al. (61) reported that a positively charged amino acid, such as arginine or lysine, at position 333 is essential for the virus to be virulent for adult mice. However, the studies of Morimoto et al. (41) strongly indicate that the arginine 333-containing region is not a receptor binding site but is essential for glycoprotein-induced cell fusion at a neutral pH. These authors further postulate that a neurotoxin-like sequence located at positions 189 to 214 is a collaborating region in giant cell formation and possibly in viral invasion of neuronal cells.
Our present efforts are directed toward the isolation and characterization of a 7.12 escape mutant whose pathogenesis and glycoprotein sequence can be compared with those of other existing mutants that have been previously studied (8, 20, 31) to clarify some of these areas of uncertainty.
For the present, at the very least, we have succeeded in defining one receptor and producing antibody to it. Our brief study of the distribution of the receptor in the central nervous system is consistent with the findings of those who have used other means to detect cholinergic nerve terminals in the central nervous system (56) . Whether AChR receptor (56) . We do not know, with certainty, from the present study whether virus infection destroys the B9 receptor in the brain. Whether B9 antibody targets a critical protein related to the spread of virus in cells of the central nervous system is another question that remains to be addressed before the importance of the B9 receptor in rabies virus pathogenesis can be properly assessed. These and other related subjects are treated in a separate report (57) .
